Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Assets (2023 - 2025)

Immunome's Current Assets history spans 3 years, with the latest figure at $660.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 198.54% year-over-year to $660.8 million; the TTM value through Dec 2025 reached $660.8 million, up 198.54%, while the annual FY2025 figure was $660.8 million, 198.54% up from the prior year.
  • Current Assets reached $660.8 million in Q4 2025 per IMNM's latest filing, up from $279.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $660.8 million in Q4 2025 to a low of $39.5 million in Q2 2023.
  • Average Current Assets over 3 years is $243.9 million, with a median of $260.7 million recorded in 2024.
  • Peak YoY movement for Current Assets: soared 619.23% in 2024, then dropped 2.41% in 2025.
  • A 3-year view of Current Assets shows it stood at $144.7 million in 2023, then surged by 52.96% to $221.3 million in 2024, then soared by 198.54% to $660.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Current Assets are $660.8 million (Q4 2025), $279.9 million (Q3 2025), and $277.4 million (Q2 2025).